After generating interest from the likes of Pfizer and GSK, Quotient Therapeutics’ somatic genomics platform has attracted ...
GlobalData on MSN
MSD and Quotient collaborate on IBD drug targets
The somatic genomics approach analyses naturally accumulated genetic mutations within individual patient tissue.
High-sensitivity sequencing of recurrent, cell-type–specific variants aims to strengthen causal inference versus germline ...
Somatic genetic mutations naturally accumulate over a lifetime, resulting in trillions of different genomes within an individual. Through its platform, Quotient interrogates patient tissue for these ...
Merck & Co. will apply the somatic genomics platform Quotient Therapeutics to discover novel drug targets in inflammatory bowel disease (IBD), through a collaboration that could generate up to $2.2 ...
IBD is a key R&D focus for MSD, whose pipeline in the indication is currently led by tulisokibart, an anti-TL1A antibody in ...
Quotient, which originated as the consumer-facing Coupons.com in the late ’90s, is pushing deeper into programmatic media. The company has launched the Quotient Media Exchange (QMX), a digital media ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results